This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Shares of Tango Therapeutics, Inc. (TNGX) have gained 18.2% over the past four weeks to close the last trading session at $8.9, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $13 indicates a potential upside of 46.1%.The mean estimate comprises eight short-term price targets with a standard deviation of $1.31. While the lowest estimate of $11.00 indicates a 23.6% increase from ...

Summary of Tango Therapeutics Conference Call Company Overview - **Company**: Tango Therapeutics - **Focus**: Development of drugs based on the concept of synthetic lethality targeting tumor suppressor genes, with a lead program being vopimetostat, an MTAP-selective PRMT5 inhibitor [6][7] Key Points Product Development - **Vopimetostat**: - Developed for MTAP-deleted pancreatic ductal adenocarcinoma (PDAC) and lung cancer - Phase one/two study shows an overall response rate (ORR) of 27% across various difficult-to-treat cancers, with a specific ORR of 25% and median progression-free survival (PFS) of 7.2 months in second-line pancreatic cancer [7][8][13] - Comparison to current standard of care indicates favorable outcomes [7][8] Clinical Trials and FDA Interaction - **Second-line PDAC Pivotal Study**: - Plans to enroll approximately 300 patients, with a hierarchical design approved by the FDA allowing for fewer patients while still assessing PFS and overall survival (OS) [10][11][18] - The study aims to demonstrate a median PFS that is at least double the current range of 2 to 3.5 months [13][15] - The FDA meeting was described as positive, with agreement on the study design [18] Combination Studies - **Combination with RAS Inhibitors**: - Ongoing studies combining vopimetostat with daraxonrasib and zoldonrasib, with rapid enrollment noted [22][23] - The goal is to establish a first-line study in pancreatic cancer based on the combination's efficacy [35] Future Expectations - **Data Updates**: - Anticipated updates on combination studies and lung cancer data in the following year [24][43] - The company aims to show a convincing improvement in ORR for the combination therapies, targeting a response rate of 45-50% [27] Financial Position - **Cash Position**: - Current cash position is $153 million, with a recent raise of $225 million, providing a runway into 2028 for ongoing studies [62] Additional Insights - **Prognostic Factors**: - MTAP deletion linked to poorer prognosis in pancreatic cancer, which may influence study outcomes [13][14] - **Safety Profile**: - Combination therapies are reported to have clean adverse event profiles with minimal overlapping toxicity [46][47] - **Strategic Collaborations**: - Collaboration with Servier for MAT2A combination studies, with data disclosures dependent on Servier [40][41] This summary encapsulates the key aspects of Tango Therapeutics' conference call, highlighting their strategic focus, clinical developments, and financial health.

BOSTON, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), today announced that Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics, is scheduled to participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference on Wednesday, November 19 at 4:30-4:55 PM GMT / 11:30-11:55am ET. The live webcast will be available under the "Events & Presentations" tab on the “Investors” page of the Company's website on the day of the event. A replay of th ...

Core Insights - Tango Therapeutics, Inc. reported quarterly earnings of $0.13 per share, significantly exceeding the Zacks Consensus Estimate of $0.01 per share, and showing a substantial improvement from a loss of $0.27 per share a year ago, resulting in an earnings surprise of +1,200.00% [1] - The company generated revenues of $53.81 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 23.20%, compared to revenues of $11.61 million in the same quarter last year [2] - Tango Therapeutics shares have increased approximately 159.2% year-to-date, outperforming the S&P 500's gain of 16.5% [3] Earnings Outlook - The future performance of Tango Therapeutics' stock will largely depend on management's commentary during the earnings call and the company's earnings outlook, which includes current consensus earnings expectations for upcoming quarters [4][6] - The current consensus EPS estimate for the next quarter is -$0.36 on revenues of $4.84 million, and for the current fiscal year, it is -$1.04 on revenues of $52.9 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Tango Therapeutics belongs, is currently ranked in the top 39% of over 250 Zacks industries, indicating a favorable outlook for stocks within this sector [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked using tools like the Zacks Rank [5]

Vopimetostat Efficacy and Response Rates - Vopimetostat demonstrates an overall response rate (ORR) of 27% across multiple cancer types, with a median progression-free survival (mPFS) of 7.2 months in 2L MTAP-del pancreatic cancer[11][30][35] - In the histology agnostic cohort, Vopimetostat achieved a 49% ORR and mPFS of 9.1 months, supporting its potential as a best-in-class treatment[11] - Vopimetostat achieved a 49% overall response rate (ORR) in the histology agnostic cohort with a median progression-free survival (mPFS) of 9.1 months[47][50] - The drug demonstrated a strong activity across cancer types, with an ORR of 27% and mPFS of 6.4 months for all histologies, and 25% ORR with 7.2 months mPFS in 2L pancreatic cancer[54] - The median time to RECIST response for Vopimetostat is 3.5 months, indicating a relatively quick onset of efficacy[13] Clinical Trials and Future Studies - The pivotal study for Vopimetostat in 2L pancreatic cancer is planned to start in 2026, targeting 150 patients with MTAP deletion[37][38] - The company anticipates rapid enrollment of ~300 patients for the pivotal study due to high unmet medical need in the target population[38] - Vopimetostat's pivotal trial design is expected to be finalized in an upcoming FDA interaction, focusing on MTAP-del patients[38] - The ongoing combination study of Vopimetostat with RAS inhibitors shows robust enrollment and plans to expand to first-line cohorts[11][40] - The ongoing study has the potential to support a first-line pivotal study with shorter timelines than competitors[43] - Ongoing combination studies of Vopimetostat with daraxonrasib or zoldonrasib may provide a pathway to first-line registration in pancreatic and lung cancer[54] - Enrollment for the Vopimetostat lung cancer cohort is fully completed with 41 patients, and an update is planned for 2026[44] Patient Population and Safety Profile - The patient population for Vopimetostat development includes approximately 60,000 patients per year in the US, with key indications in pancreatic cancer (~20,000 patients/year) and lung cancer (~22,000 patients/year)[5] - Vopimetostat has a favorable safety profile, with 0% discontinuation due to drug-related events and only 8% of patients requiring dose reduction[25][22] - The median follow-up for tumor evaluable patients was 9.5 months, with 21 out of 37 patients ongoing[50] - Vopimetostat has shown durable activity in multiple lines of difficult-to-treat cancers, providing further evidence of single-agent activity[53] Dosage and Administration - The FDA has aligned on a 250 mg QD go-forward dose for Vopimetostat[54]

Financial Overview - Tango Therapeutics has raised an aggregate of $166.9 million from preferred shares, $342.1 million from a Business Combination, $237.1 million from a collaboration with Gilead, and $348.0 million from various financing transactions[118]. - As of September 30, 2025, the company had cash, cash equivalents, and marketable securities totaling $152.8 million, which, along with $212.0 million from a recent offering, is expected to fund operations into 2028[119]. - For the nine months ended September 30, 2025, the company reported a net loss of $62.8 million, compared to a net loss of $92.6 million for the same period in 2024, with an accumulated deficit of $564.4 million[119]. - The company has not generated any revenue from product sales and does not expect to do so in the next several years, relying on equity offerings and collaborations for funding[120]. - Total revenue for the nine months ended September 30, 2025, was $62.4 million, up from $25.9 million in 2024, marking a $36.5 million increase[155]. Collaboration Revenue - Tango Therapeutics recognized $53.8 million in collaboration revenue for the three months ended September 30, 2025, compared to $11.6 million for the same period in 2024[128]. - The total collaboration revenue recognized from the Gilead agreements as of September 30, 2025, amounts to $199.0 million, which includes upfront and research option-extension payments[127]. - Collaboration revenue increased to $53.8 million for the three months ended September 30, 2025, compared to $11.6 million for the same period in 2024, reflecting a $42.2 million increase[148]. Clinical Trials and Product Development - The ongoing Phase 1/2 clinical trial of vopimetostat showed an objective response rate (ORR) of 27% and a median progression-free survival (mPFS) of 6.4 months across all MTAP-deleted tumor types[110]. - In the cohort of 29 patients with second-line MTAP-deleted pancreatic cancer, the mPFS was 7.2 months, and the ORR was 25%, significantly higher than historical chemotherapy studies[110]. - TNG260 demonstrated a median progression-free survival of 27 weeks in patients with STK11-mutant, locally advanced or metastatic solid tumors, more than double the standard of care[116]. - The company plans to initiate a pivotal trial in second-line pancreatic cancer in 2026, supported by newly engaged consultants with significant oncology expertise[112]. Expenses and Income - Research and development expenses decreased to $30.8 million for the three months ended September 30, 2025, down from $33.3 million in 2024, a reduction of $2.5 million[149]. - Total operating expenses for the three months ended September 30, 2025, were $39.7 million, a decrease of $4.7 million from $44.5 million in 2024[147]. - Net income for the three months ended September 30, 2025, was $15.9 million, compared to a net loss of $29.2 million in 2024, an improvement of $45.1 million[147]. - Research and development expenses for the nine months ended September 30, 2025, totaled $100.1 million, down from $110.0 million in 2024, a decrease of $9.9 million[157]. - General and administrative expenses for the nine months ended September 30, 2025, were $31.7 million, a slight decrease from $32.7 million in 2024[158]. Cash Flow and Financing Activities - Net cash used in operating activities increased to $109.2 million for the nine months ended September 30, 2025, compared to $94.9 million for the same period in 2024, primarily due to a decrease in operating assets and liabilities[166]. - Net cash provided by investing activities rose to $94.9 million for the nine months ended September 30, 2025, from $34.1 million in 2024, mainly due to a decrease in purchases of marketable securities[167]. - Net cash provided by financing activities was $3.1 million for the nine months ended September 30, 2025, a significant decrease from $46.7 million in the same period of 2024[168]. - The company expects existing cash and net proceeds from the recent offering to fund operating expenses and capital expenditures into 2028, although this estimate is based on assumptions that may prove incorrect[164]. Tax and Other Income - Provision for income taxes was $0.1 million for the nine months ended September 30, 2025, compared to $0.2 million for the same period in 2024, indicating an insignificant tax provision in both periods[161]. - Other income, net decreased to $2.7 million for the nine months ended September 30, 2025, from $6.1 million in the same period of 2024, attributed to lower accretion from investments purchased at a discount[160]. - Interest income for the three months ended September 30, 2025, was $1.1 million, down from $1.8 million in 2024, a decrease of $0.7 million[151]. Accounting and Market Risks - Revenue recognition is based on ASC Topic 606, with revenue recognized when control of promised goods or services is transferred to a customer[175]. - The company estimates accrued research and development expenses based on the level of service performed and associated costs incurred, with adjustments made as necessary[183]. - The company records expenses related to research and development activities based on estimates of services received, considering factors such as progress towards completion and invoicing to date[185]. - There have been no material adjustments to prior estimates of accrued research and development expenses to date[185]. - Recently adopted accounting pronouncements that may impact financial position and cash flows are disclosed in the Quarterly Report on Form 10-Q and the Annual Report on Form 10-K[186]. - There were no material changes to market risks from those described in the Annual Report on Form 10-K for the year ended December 31, 2024[187].

Core Insights - Tango Therapeutics reported promising clinical data for vopimetostat (TNG462), indicating a median progression-free survival (mPFS) of 7.2 months in patients with second-line MTAP-del pancreatic cancer, supporting the initiation of a pivotal trial in 2026 [1][5] - The company secured $225 million in financing, extending its cash runway into 2028, which will support ongoing clinical studies and development plans [1][2] - The combination studies of vopimetostat with RAS(ON) inhibitors are progressing well, with initial data expected in 2026 [1][2] Clinical Development - Vopimetostat demonstrated a 49% overall response rate (ORR) and a mPFS of 9.1 months in a histology-selective cohort of difficult-to-treat cancers, providing evidence of its strong activity [1][5] - The ongoing combination study of vopimetostat with RAS(ON) inhibitors is well-tolerated, with initial data anticipated in 2026 [5] - TNG456, another candidate, received Orphan Drug Designation (ODD) for malignant glioma, which offers marketing exclusivity and incentives upon regulatory approval [4][5] Financial Performance - As of September 30, 2025, the company reported $152.8 million in cash and equivalents, bolstered by $212 million in net proceeds from a public offering, ensuring operational funding through 2028 [8] - Collaboration revenue increased significantly to $53.8 million for Q3 2025, compared to $11.6 million in Q3 2024, driven by the conclusion of a collaboration agreement with Gilead [9] - The net income for Q3 2025 was $15.9 million, a turnaround from a net loss of $29.2 million in the same period of 2024 [14] Upcoming Milestones - The company plans to initiate a pivotal study for vopimetostat in second-line pancreatic cancer in 2026, alongside updates from ongoing studies [2][6] - Initial safety and efficacy data from the combination trials of vopimetostat with RAS(ON) inhibitors are expected in 2026 [11][12] - The lung cancer cohort of the vopimetostat study is fully enrolled, with updates planned for 2026 [5][11]

Company Overview - Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing novel cancer therapies using synthetic lethality, targeting genetically-defined tumors [7][8] - The company has a strategic collaboration with Gilead Sciences, Inc. for the development and commercialization of cancer therapies [8][9] - As of October 23, 2025, Tango Therapeutics had a market capitalization of $1.05 billion and a revenue of $24.30 million for the trailing twelve months (TTM) [6] Transaction Summary - Third Rock Ventures IV, L.P. sold 477,401 shares of Tango Therapeutics on October 23, 2025, for a total transaction value of approximately $4.85 million [2][3] - Post-transaction, Third Rock Ventures IV, L.P. holds 13,386,574 shares, representing 12.03% of the outstanding shares [3][5] - The sale represented 3.44% of Third Rock Ventures IV, L.P.'s direct ownership as of the transaction date [3] Market Context - The shares were sold at a price of approximately $10.15, which was the weighted average purchase price for the transaction [4] - The stock price had increased nearly 160% in 2025 through October 30, and reached a 52-week high on October 16, 2025 [10][11] Financial Performance - Tango Therapeutics reported a significant decline in revenue in 2025, with Q2 sales of $3.2 million compared to $19.9 million in the same quarter of the previous year [12] - The company experienced an operating loss of $41 million in Q2 2025 [12] Investment Considerations - The sale by Third Rock Ventures is viewed as profit-taking, but the venture capital fund still maintains a significant investment in Tango Therapeutics [10][11] - The current price-to-sales ratio of Tango Therapeutics is 35, indicating that shares may be considered expensive at this time [13]